These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38365541)

  • 21. Quality assessment of neoadjuvant therapy use in breast conservation: barriers to implementation.
    James T; McCahill L; Ratliff J; Ashikaga T; Single R; Sheehey-Jones J; Messier N; Stanley M; Krag D; Harlow S
    Breast J; 2009; 15(5):524-6. PubMed ID: 19624412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
    Simons JM; Koppert LB; Luiten EJT; van der Pol CC; Samiei S; de Wilt JHW; Siesling S; Smidt ML
    Breast Cancer Res Treat; 2020 Apr; 180(3):725-733. PubMed ID: 32180074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment.
    Siso C; Esgueva A; Rivero J; Morales C; Miranda I; Peg V; Gil-Moreno A; Espinosa-Bravo M; Rubio IT
    Eur J Surg Oncol; 2023 Oct; 49(10):106938. PubMed ID: 37244843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
    Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
    J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial.
    Yamaguchi T; Hozumi Y; Sagara Y; Takahashi M; Yoneyama K; Fujisawa T; Osumi S; Akabane H; Nishimura R; Mieno MN; Mukai H
    Surg Oncol; 2021 Mar; 36():51-55. PubMed ID: 33310293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Impact of Neoadjuvant Treatment on Surgical Options and Outcomes.
    Ataseven B; von Minckwitz G
    Ann Surg Oncol; 2016 Oct; 23(10):3093-9. PubMed ID: 27364505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges.
    Heil J; Kuerer HM; Pfob A; Rauch G; Sinn HP; Golatta M; Liefers GJ; Vrancken Peeters MJ
    Ann Oncol; 2020 Jan; 31(1):61-71. PubMed ID: 31912797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Neoadjuvant systemic therapy for breast cancer].
    Semiglazov VF
    Vopr Onkol; 2015; 61(2):162-8. PubMed ID: 26087591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer.
    Tasoulis MK; Lee HB; Yang W; Pope R; Krishnamurthy S; Kim SY; Cho N; Teoh V; Rauch GM; Smith BD; Valero V; Mohammed K; Han W; MacNeill F; Kuerer HM
    JAMA Surg; 2020 Dec; 155(12):e204103. PubMed ID: 33026457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. De-ESCAlating RadioTherapy in breast cancer patients with pathologic complete response to neoadjuvant systemic therapy: DESCARTES study.
    van Hemert AKE; van Olmen JP; Boersma LJ; Maduro JH; Russell NS; Tol J; Engelhardt EG; Rutgers EJT; Vrancken Peeters MTFD; van Duijnhoven FH
    Breast Cancer Res Treat; 2023 May; 199(1):81-89. PubMed ID: 36892723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Post operative complications after neoadjuvant systemic therapy in primary breast cancer treatment - Case-control study].
    Marszalek D; Noël JC; Simon P
    Rev Med Brux; 2016; 37(6):469-475. PubMed ID: 28525174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands.
    Vugts G; Maaskant-Braat AJ; de Roos WK; Voogd AC; Nieuwenhuijzen GA
    Eur J Surg Oncol; 2016 Jul; 42(7):956-64. PubMed ID: 27107791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment for Reliable Exclusion of Residual Cancer in Breast Cancer Patients.
    Koelbel V; Pfob A; Schaefgen B; Sinn P; Feisst M; Golatta M; Gomez C; Stieber A; Bach P; Rauch G; Heil J
    Ann Surg Oncol; 2022 Feb; 29(2):1076-1084. PubMed ID: 34581923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. De-escalation towards omission is the tipping point of individualizing breast cancer surgery.
    Heil J; Pfob A; Kuerer HM
    Eur J Surg Oncol; 2020 Aug; 46(8):1543-1545. PubMed ID: 32241595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility of breast conserving surgery alone in HER2-positive exceptional responders to neoadjuvant systemic therapy.
    Mitchell MP; Shaitelman SF; Smith BD; Krishnamurthy S; Valero V; Rauch GM; Shen Y; Lin H; Kuerer HM
    Eur J Surg Oncol; 2024 Dec; 50(12):108613. PubMed ID: 39243728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03.
    Heil J; Pfob A; Sinn HP; Rauch G; Bach P; Thomas B; Schaefgen B; Kuemmel S; Reimer T; Hahn M; Thill M; Blohmer JU; Hackmann J; Malter W; Bekes I; Friedrichs K; Wojcinski S; Joos S; Paepke S; Ditsch N; Rody A; Große R; van Mackelenbergh M; Reinisch M; Karsten M; Golatta M;
    Ann Surg; 2022 Mar; 275(3):576-581. PubMed ID: 32657944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.
    Groen EJ; van der Noordaa MEM; Schaapveld M; Sonke GS; Mann RM; van Ramshorst MS; Lips EH; Vrancken Peeters MTFD; van Duijnhoven FH; Wesseling J
    Breast Cancer Res Treat; 2021 Aug; 189(1):213-224. PubMed ID: 33945043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study.
    van Loevezijn AA; van der Noordaa MEM; van Werkhoven ED; Loo CE; Winter-Warnars GAO; Wiersma T; van de Vijver KK; Groen EJ; Blanken-Peeters CFJM; Zonneveld BJGL; Sonke GS; van Duijnhoven FH; Vrancken Peeters MTFD
    Ann Surg Oncol; 2021 Jun; 28(6):3243-3253. PubMed ID: 33263830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic Therapy Advances for HER2-Positive and Triple Negative Breast Cancer: What the Surgeon Needs to Know.
    Downs-Canner S; Weiss A
    Clin Breast Cancer; 2024 Jun; 24(4):328-336. PubMed ID: 38616443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.